Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GTBP GT Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: GTBP
Price (delayed)
$3.21
Market cap
$8.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.69
Enterprise value
$5.84M
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform
Highlights
The debt has shrunk by 100% YoY
GTBP's EPS is up by 20% year-on-year and by 18% since the previous quarter
GT Biopharma's equity has shrunk by 118% YoY but it has increased by 41% QoQ
The company's net income fell by 21% YoY but it rose by 11% QoQ
GT Biopharma's quick ratio has shrunk by 68% YoY
Key stats
What are the main financial stats of GTBP
Market
Valuations
Earnings
Shares outstanding
2.59M
Market cap
$8.3M
Enterprise value
$5.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$13.21M
Net income
-$11.67M
EBIT
-$11.67M
EBITDA
-$11.67M
Free cash flow
-$10.94M
Per share
Balance sheet
Liquidity
EPS
-$5.69
EPS diluted
-$5.69
Free cash flow per share
-$4.67
Book value per share
-$0.44
Revenue per share
$0
TBVPS
$1.13
Total assets
$2.66M
Total liabilities
$3.64M
Debt
$0
Equity
-$980,000
Working capital
-$980,000
Debt to equity
0
Current ratio
0.73
Quick ratio
0.68
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-203.7%
Return on equity
-942.2%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GTBP stock price
How has the GT Biopharma stock price performed over time
Intraday
5.25%
1 week
13.83%
1 month
11.07%
1 year
9.93%
YTD
5.25%
QTD
49.3%
Financial performance
How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.21M
Net income
-$11.67M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 21% YoY but it rose by 11% QoQ
GTBP's operating income is up by 8% since the previous quarter
Price vs fundamentals
How does GTBP's price correlate with its fundamentals
Growth
What is GT Biopharma's growth rate over time
Valuation
What is GT Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS is up by 20% year-on-year and by 18% since the previous quarter
GT Biopharma's equity has shrunk by 118% YoY but it has increased by 41% QoQ
Efficiency
How efficient is GT Biopharma business performance
GTBP's ROE has dropped by 101% since the previous quarter
The company's return on assets fell by 17% QoQ
Dividends
What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GTBP.
Financial health
How did GT Biopharma financials performed over time
GT Biopharma's total assets is 27% less than its total liabilities
GT Biopharma's total assets has plunged by 73% YoY and by 37% from the previous quarter
GT Biopharma's quick ratio has shrunk by 68% YoY
The debt is 100% higher than the equity
GT Biopharma's equity has shrunk by 118% YoY but it has increased by 41% QoQ
The debt has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.